ArticleChinese medicine2025
Spinal dorsal horn IGF1 mediates the preventive effect of electroacupuncture on cisplatin-induced peripheral neuropathy via neuronal IGF1R in mice.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model.Frontiers in immunology · 2026Pooled it
- Efficacy and Proposed Mechanisms of Electroacupuncture in Animal Models of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur previous study demonstrated that neuronal G protein-coupled receptor kinase (GRK2) upregulation alleviated chemotherapy-induced peripheral neuropathy (CIPN) in mice, which was characterized by numbness and pain in distal hind limbs. The neuronal GRK2 was identified as a mediator of electroacupuncture (EA) effects on CIPN. Given that spinal insulin-like growth factor 1 (IGF1), a known inducer of GRK2 in the peripheral neurons, decreases after oxaliplatin treatment in mice, this study is designed to investigate whether spinal IGF1 contributes to EA-mediated prevention of cisplatin-induced peripheral neuropathy via neuronal IGF1 receptor (IGF1R).
methodsA total of 133 male C57BL/6 J mice were included in this study and randomly assigned to different experimental groups. The level of Igf1 mRNA was detected by Real-time PCR, the p-IGF1R protein level by Western blot, after EA treatment in cisplatin-treated mice. The cellular distribution of p-IGF1R in the spinal dorsal horn was observed by immunofluorescent staining. To study the role of neuronal IGF1R in EA preventing cisplatin-induced mechanical allodynia, sensory deficit, and microglia activation and neuroinflammation in the spinal cord of mice, the neuronal IGF1R was downregulated by intraspinal injection of an AAV vector delivering IGF1R shRNA with hSyn promotor (AAV-shIGF1R). Finally, the regulatory effect of EA on spinal GRK2 was assessed by Western blot in AAV-shIGF1R mice.
resultsCisplatin treatment induced mechanical allodynia, sensory deficit, and a decrease of p-IGF1R in the spinal dorsal horn of mice. Immunofluorescence showed that p-IGF1R was localized within neurons (~ 82%), a small mount of microglia (~ 12%) and astrocytes (~ 4%). Cisplatin decreased NeuN
conclusionSpinal dorsal horn IGF1 contributes to the preventive effect of EA treatment against cisplatin-induced peripheral neuropathy through neuronal IGF1R signaling in mice. The enhanced neuronal IGF1/IGF1R signaling in the spinal cord presents a potential strategy for CIPN prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.